Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Manufacturing

Lilly investing billions to prepare for overseas oral GLP-1 launches

 April 14, 2026

BioSpace

With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity dr

ManufacturingMetabolic & GLP-1Read full story

Post navigation

FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development →
← Lilly boosts ADC portfolio with CrossBridge Bio deal

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com